Tab. III.
Budget impact analysis, considering PrEP as an add-on strategy to condoms and NSPs.
| 100% PrEP reimbursed by the Italian NHS, considering branded drugs | 100% PrEP purchased by citizens, considering branded drugs | |||||||
|---|---|---|---|---|---|---|---|---|
| Italian NHS point of view | Italian NHS point of view | |||||||
| Baseline scenario | Innovative scenario | Difference | Difference % |
Baseline scenario | Innovative scenario | Difference | Difference % |
|
| MSM and sexual risk | € 47,049,798 | € 114,119,651 | € 67,069,852 | 143% | € 47,049,798 | € 20,491,208 | -€ 26,558,590 | -56% |
| SCs | € 52,670,757 | € 131,873,657 | € 79,202,900 | 150% | € 52,670,757 | € 29,012,864 | -€ 23,657,893 | -45% |
| IDUs | € 99,007,920 | € 31,559,987 | -€ 67,447,933 | -68% | € 99,007,920 | € 24,948,467 | -€ 74,059,453 | -75% |
| Total high-risk population | € 198,728,475 | € 277,553,294 | € 78,824,819 | 40% | € 198,728,475 | € 74,452,539 | -€ 124,275,936 | -63% |
| PrEP users' point of view | PrEP users' point of view | |||||||
| Baseline scenario | Innovative scenario | Difference | Difference % | Baseline scenario | Innovative scenario | Difference | Difference % | |
| MSM and sexual risk | € 5,183,416 | € 6,720,833 | € 1,537,416 | 30% | € 5,183,416 | € 164,720,834 | € 159,537,418 | 3078% |
| SCs | € 5,802,670 | € 7,120,791 | € 1,318,121 | 23% | € 5,802,670 | € 180,700,582 | € 174,897,912 | 3014% |
| IDUs | € 6,498,759 | € 2,778,990 | -€ 3,719,769 | -57% | € 6,498,759 | € 87,616,622 | € 81,117,862 | 1248% |
| Total high-risk population | € 17,484,846 | € 16,620,614 | -€ 864,232 | -5% | € 17,484,846 | € 433,038,038 | € 415,553,192 | 2377% |
| 100% PrEP reimbursed by the Italian NHS, considering off-patent drugs | 100% PrEP purchased by citizens, considering of patent drugs | |||||||
| Italian NHS point of view | Italian NHS point of view | |||||||
| Baseline scenario | Innovative scenario | Difference | Difference % | Baseline scenario | Innovative scenario | Difference | Difference % | |
| MSM and sexual risk | € 47,049,798 | € 48,579,741 | € 1,529,943 | 3% | € 47,049,798 | € 20,491,208 | -€ 26,558,590 | -56% |
| SCs | € 52,670,757 | € 59,871,102 | € 7,200,345 | 14% | € 52,670,757 | € 29,012,864 | -€ 23,657,893 | -45% |
| IDUs | € 99,007,920 | € 16,772,989 | -€ 82,234,931 | -83% | € 99,007,920 | € 24,948,467 | -€ 74,059,453 | -75% |
| Total high-risk population | € 198,728,475 | € 125,223,832 | -€ 73,504,643 | -37% | € 198,728,475 | € 74,452,539 | -€ 124,275,936 | -63% |
| PrEP users' point of view | PrEP users' point of view | |||||||
| Baseline scenario | Innovative scenario | Difference | Difference % | Baseline scenario | Innovative scenario | Difference | Difference % | |
| MSM and sexual risk | € 5,183,416 | € 6,720,833 | € 1,537,416 | 30% | € 5,183,416 | € 54,120,833 | € 48,937,417 | 944% |
| SCs | € 5,802,670 | € 7,120,791 | € 1,318,121 | 23% | € 5,802,670 | € 59,194,728 | € 53,392,058 | 920% |
| IDUs | € 6,498,759 | € 2,778,990 | -€ 3,719,769 | -57% | € 6,498,759 | € 30,040,415 | € 23,541,656 | 362% |
| Total high-risk population | € 17,484,846 | € 16,620,614 | -€ 864,232 | -5% | € 17,484,846 | € 143,355,976 | € 125,871,130 | 720% |